MGMT and central nervous system cancer: In addition, we established a nomogram that integrates the prognosis model with clinicopathological factors (age, gender, grade, IDH mutation status, 1p19q codeletion status and MGMT promoter methylation status) and found its performance in estimating 1‐, 3‐ and 5‐year survival rates of glioma patients is excellent.